Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 30:56:173-177.
doi: 10.1016/j.amsu.2020.06.035. eCollection 2020 Aug.

Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: A review

Ganesh Kasinathan  1 , Jameela Sathar  1
Affiliations
Review

Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: A review

Ganesh Kasinathan et al. Ann Med Surg (Lond). .

Abstract

Coronavirus-19 disease (COVID-19), a zoonosis, was first reported in the city of Wuhan, province of Hubei, China in December 2019. The disease is caused by the Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2). As of 12th of May 2020, 4,256,022 confirmed cases affecting 212 countries with 287,332 deaths have been reported. The common symptoms reported in patients with COVID-19 are fever, dry cough, dyspnoea and gastrointestinal symptoms such as vomiting and diarrhoea. Non-survivors often succumb due to widespread pulmonary intravascular coagulopathy, arterial and venous thromboembolism, disseminated intravascular coagulopathy (DIC), secondary hemophagocytic lymphohistiocytosis (sHLH), and multiorgan dysfunctional syndrome (MODS). All hospitalised patients should be monitored closely for thrombotic events. Patients who develop bleeding episodes should be managed according to standard DIC guidelines. The main objectives of this review are 1) to provide a succinct background of this novel disease 2) discuss the haematological presentations and mechanisms of thrombosis 3) emphasize the role of anti-coagulation prophylaxis 4) explore the management of coagulopathy 5) provide insight on management of patients with COVID-19 disease and pre-existing bleeding disorders.

Keywords: Bleeding episodes; Coronavirus-19 disease; Pulmonary intravascular coagulopathy; Thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Both authors declare no potential conflicts of interests.

References

    1. Hui D.S., Azhar E., Madani T.A. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 2020;91:264–266. - PMC - PubMed
    1. Layton D.S., Choudhary A., Bean A.G.D. Breaking the chain of zoonoses through biosecurity in livestock. Vaccine. 2017;35:5967–5973. - PubMed
    1. Ong S.W., Tan Y.K., Chia P.Y. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. J. Am. Med. Assoc. 2020 (Epub ahead of print) - PMC - PubMed
    1. Li D., Jin M., Bao P.T. Clinical characteristics and results of semen tests among men with coronavirus disease 2019. JAMA Netw. Open. 2020;3(5) - PMC - PubMed
    1. Zhu N., Zhang D., Wang W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382(8):727–733. - PMC - PubMed